(2S)-2-(3-(1-carboxy-5-(4-211At-astatobenzamido)pentyl) ureido)-pentanedioic acid for PSMA-targeted α-particle radiopharmaceutical therapy

Ana P. Kiess, Il Minn, Ganesan Vaidyanathan, Robert F. Hobbs, Anders Josefsson, Colette Shen, Mary Brummet, Ying Chen, Jaeyeon Choi, Eftychia Koumarianou, Kwamena Baidoo, Martin W. Brechbiel, Ronnie C. Mease, George Sgouros, Michael R. Zalutsky, Martin G. Pomper

Research output: Research - peer-reviewArticle

Abstract

Alpha-particle emitters have a high linear energy transfer and short range, offering the potential for treating micrometastases while sparing normal tissues. We developed a urea-based, 211At-labeled small molecule targeting prostate-specific membrane antigen (PSMA) for the treatment of micrometastases due to prostate cancer (PC). Methods: PSMA-targeted (2S)-2-(3-(1-carboxy-5-(4-211At-astatobenzamido) pentyl)ureido)-pentanedioic acid (211At-6) was synthesized. Cellular uptake and clonogenic survival were tested in PSMA-positive (PSMA+) PC3 PIP and PSMA-negative (PSMA-) PC3 flu human PC cells after 211At-6 treatment. The antitumor efficacy of 211At-6 was evaluated in mice bearing PSMA+ PC3 PIP and PSMA- PC3 flu flank xenografts at a 740-kBq dose and in mice bearing PSMA+, luciferase-expressing PC3-ML micrometastases. Biodistribution was determined in mice bearing PSMA+ PC3 PIP and PSMA-PC3 flu flank xenografts. Suborgan distribution was evaluated using α-camera images, and microscale dosimetry was modeled. Long-term toxicity was assessed in mice for 12 mo. Results: 211At-6 treatment resulted in PSMA-specific cellular uptake and decreased clonogenic survival in PSMA+ PC3 PIP cells and caused significant tumor growth delay in PSMA+ PC3 PIP flank tumors. Significantly improved survival was achieved in the newly developed PSMA+ micrometastatic PC model. Biodistribution showed uptake of 211At-6 in PSMA+ PC3 PIP tumors and in kidneys. Microscale kidney dosimetry based on α-camera images and a nephron model revealed hot spots in the proximal renal tubules. Long-term toxicity studies confirmed that the dose-limiting toxicity was late radiation nephropathy. Conclusion: PSMA-targeted 211At-6 α-particle radiotherapy yielded significantly improved survival in mice bearing PC micrometastases after systemic administration. 211At-6 also showed uptake in renal proximal tubules resulting in late nephrotoxicity, highlighting the importance of long-term toxicity studies and microscale dosimetry.

LanguageEnglish (US)
Pages1569-1575
Number of pages7
JournalJournal of Nuclear Medicine
Volume57
Issue number10
DOIs
StatePublished - Oct 1 2016

Fingerprint

Alpha Particles
Radiopharmaceuticals
Acids
Therapeutics
human glutamate carboxypeptidase II
Neoplasm Micrometastasis
Prostatic Neoplasms
Neoplasms
mouse PSMA protein
Proximal Kidney Tubule
Heterografts
Kidney
Linear Energy Transfer
Nephrons
Luciferases
Human Influenza
Urea
Radiotherapy
Radiation
Growth

Keywords

  • Alpha emitter
  • Astatine
  • Oncology: GU
  • Prostate cancer
  • Prostate-specific membrane antigen
  • Radiation dosimetry
  • Radionuclide therapy
  • Radiopharmaceuticals

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

(2S)-2-(3-(1-carboxy-5-(4-211At-astatobenzamido)pentyl) ureido)-pentanedioic acid for PSMA-targeted α-particle radiopharmaceutical therapy. / Kiess, Ana P.; Minn, Il; Vaidyanathan, Ganesan; Hobbs, Robert F.; Josefsson, Anders; Shen, Colette; Brummet, Mary; Chen, Ying; Choi, Jaeyeon; Koumarianou, Eftychia; Baidoo, Kwamena; Brechbiel, Martin W.; Mease, Ronnie C.; Sgouros, George; Zalutsky, Michael R.; Pomper, Martin G.

In: Journal of Nuclear Medicine, Vol. 57, No. 10, 01.10.2016, p. 1569-1575.

Research output: Research - peer-reviewArticle

Kiess, Ana P. ; Minn, Il ; Vaidyanathan, Ganesan ; Hobbs, Robert F. ; Josefsson, Anders ; Shen, Colette ; Brummet, Mary ; Chen, Ying ; Choi, Jaeyeon ; Koumarianou, Eftychia ; Baidoo, Kwamena ; Brechbiel, Martin W. ; Mease, Ronnie C. ; Sgouros, George ; Zalutsky, Michael R. ; Pomper, Martin G./ (2S)-2-(3-(1-carboxy-5-(4-211At-astatobenzamido)pentyl) ureido)-pentanedioic acid for PSMA-targeted α-particle radiopharmaceutical therapy. In: Journal of Nuclear Medicine. 2016 ; Vol. 57, No. 10. pp. 1569-1575
@article{3919488512bb44c2b4f1b440d8b98962,
title = "(2S)-2-(3-(1-carboxy-5-(4-211At-astatobenzamido)pentyl) ureido)-pentanedioic acid for PSMA-targeted α-particle radiopharmaceutical therapy",
abstract = "Alpha-particle emitters have a high linear energy transfer and short range, offering the potential for treating micrometastases while sparing normal tissues. We developed a urea-based, 211At-labeled small molecule targeting prostate-specific membrane antigen (PSMA) for the treatment of micrometastases due to prostate cancer (PC). Methods: PSMA-targeted (2S)-2-(3-(1-carboxy-5-(4-211At-astatobenzamido) pentyl)ureido)-pentanedioic acid (211At-6) was synthesized. Cellular uptake and clonogenic survival were tested in PSMA-positive (PSMA+) PC3 PIP and PSMA-negative (PSMA-) PC3 flu human PC cells after 211At-6 treatment. The antitumor efficacy of 211At-6 was evaluated in mice bearing PSMA+ PC3 PIP and PSMA- PC3 flu flank xenografts at a 740-kBq dose and in mice bearing PSMA+, luciferase-expressing PC3-ML micrometastases. Biodistribution was determined in mice bearing PSMA+ PC3 PIP and PSMA-PC3 flu flank xenografts. Suborgan distribution was evaluated using α-camera images, and microscale dosimetry was modeled. Long-term toxicity was assessed in mice for 12 mo. Results: 211At-6 treatment resulted in PSMA-specific cellular uptake and decreased clonogenic survival in PSMA+ PC3 PIP cells and caused significant tumor growth delay in PSMA+ PC3 PIP flank tumors. Significantly improved survival was achieved in the newly developed PSMA+ micrometastatic PC model. Biodistribution showed uptake of 211At-6 in PSMA+ PC3 PIP tumors and in kidneys. Microscale kidney dosimetry based on α-camera images and a nephron model revealed hot spots in the proximal renal tubules. Long-term toxicity studies confirmed that the dose-limiting toxicity was late radiation nephropathy. Conclusion: PSMA-targeted 211At-6 α-particle radiotherapy yielded significantly improved survival in mice bearing PC micrometastases after systemic administration. 211At-6 also showed uptake in renal proximal tubules resulting in late nephrotoxicity, highlighting the importance of long-term toxicity studies and microscale dosimetry.",
keywords = "Alpha emitter, Astatine, Oncology: GU, Prostate cancer, Prostate-specific membrane antigen, Radiation dosimetry, Radionuclide therapy, Radiopharmaceuticals",
author = "Kiess, {Ana P.} and Il Minn and Ganesan Vaidyanathan and Hobbs, {Robert F.} and Anders Josefsson and Colette Shen and Mary Brummet and Ying Chen and Jaeyeon Choi and Eftychia Koumarianou and Kwamena Baidoo and Brechbiel, {Martin W.} and Mease, {Ronnie C.} and George Sgouros and Zalutsky, {Michael R.} and Pomper, {Martin G.}",
year = "2016",
month = "10",
doi = "10.2967/jnumed.116.174300",
volume = "57",
pages = "1569--1575",
journal = "Journal of Nuclear Medicine",
issn = "0161-5505",
publisher = "Society of Nuclear Medicine Inc.",
number = "10",

}

TY - JOUR

T1 - (2S)-2-(3-(1-carboxy-5-(4-211At-astatobenzamido)pentyl) ureido)-pentanedioic acid for PSMA-targeted α-particle radiopharmaceutical therapy

AU - Kiess,Ana P.

AU - Minn,Il

AU - Vaidyanathan,Ganesan

AU - Hobbs,Robert F.

AU - Josefsson,Anders

AU - Shen,Colette

AU - Brummet,Mary

AU - Chen,Ying

AU - Choi,Jaeyeon

AU - Koumarianou,Eftychia

AU - Baidoo,Kwamena

AU - Brechbiel,Martin W.

AU - Mease,Ronnie C.

AU - Sgouros,George

AU - Zalutsky,Michael R.

AU - Pomper,Martin G.

PY - 2016/10/1

Y1 - 2016/10/1

N2 - Alpha-particle emitters have a high linear energy transfer and short range, offering the potential for treating micrometastases while sparing normal tissues. We developed a urea-based, 211At-labeled small molecule targeting prostate-specific membrane antigen (PSMA) for the treatment of micrometastases due to prostate cancer (PC). Methods: PSMA-targeted (2S)-2-(3-(1-carboxy-5-(4-211At-astatobenzamido) pentyl)ureido)-pentanedioic acid (211At-6) was synthesized. Cellular uptake and clonogenic survival were tested in PSMA-positive (PSMA+) PC3 PIP and PSMA-negative (PSMA-) PC3 flu human PC cells after 211At-6 treatment. The antitumor efficacy of 211At-6 was evaluated in mice bearing PSMA+ PC3 PIP and PSMA- PC3 flu flank xenografts at a 740-kBq dose and in mice bearing PSMA+, luciferase-expressing PC3-ML micrometastases. Biodistribution was determined in mice bearing PSMA+ PC3 PIP and PSMA-PC3 flu flank xenografts. Suborgan distribution was evaluated using α-camera images, and microscale dosimetry was modeled. Long-term toxicity was assessed in mice for 12 mo. Results: 211At-6 treatment resulted in PSMA-specific cellular uptake and decreased clonogenic survival in PSMA+ PC3 PIP cells and caused significant tumor growth delay in PSMA+ PC3 PIP flank tumors. Significantly improved survival was achieved in the newly developed PSMA+ micrometastatic PC model. Biodistribution showed uptake of 211At-6 in PSMA+ PC3 PIP tumors and in kidneys. Microscale kidney dosimetry based on α-camera images and a nephron model revealed hot spots in the proximal renal tubules. Long-term toxicity studies confirmed that the dose-limiting toxicity was late radiation nephropathy. Conclusion: PSMA-targeted 211At-6 α-particle radiotherapy yielded significantly improved survival in mice bearing PC micrometastases after systemic administration. 211At-6 also showed uptake in renal proximal tubules resulting in late nephrotoxicity, highlighting the importance of long-term toxicity studies and microscale dosimetry.

AB - Alpha-particle emitters have a high linear energy transfer and short range, offering the potential for treating micrometastases while sparing normal tissues. We developed a urea-based, 211At-labeled small molecule targeting prostate-specific membrane antigen (PSMA) for the treatment of micrometastases due to prostate cancer (PC). Methods: PSMA-targeted (2S)-2-(3-(1-carboxy-5-(4-211At-astatobenzamido) pentyl)ureido)-pentanedioic acid (211At-6) was synthesized. Cellular uptake and clonogenic survival were tested in PSMA-positive (PSMA+) PC3 PIP and PSMA-negative (PSMA-) PC3 flu human PC cells after 211At-6 treatment. The antitumor efficacy of 211At-6 was evaluated in mice bearing PSMA+ PC3 PIP and PSMA- PC3 flu flank xenografts at a 740-kBq dose and in mice bearing PSMA+, luciferase-expressing PC3-ML micrometastases. Biodistribution was determined in mice bearing PSMA+ PC3 PIP and PSMA-PC3 flu flank xenografts. Suborgan distribution was evaluated using α-camera images, and microscale dosimetry was modeled. Long-term toxicity was assessed in mice for 12 mo. Results: 211At-6 treatment resulted in PSMA-specific cellular uptake and decreased clonogenic survival in PSMA+ PC3 PIP cells and caused significant tumor growth delay in PSMA+ PC3 PIP flank tumors. Significantly improved survival was achieved in the newly developed PSMA+ micrometastatic PC model. Biodistribution showed uptake of 211At-6 in PSMA+ PC3 PIP tumors and in kidneys. Microscale kidney dosimetry based on α-camera images and a nephron model revealed hot spots in the proximal renal tubules. Long-term toxicity studies confirmed that the dose-limiting toxicity was late radiation nephropathy. Conclusion: PSMA-targeted 211At-6 α-particle radiotherapy yielded significantly improved survival in mice bearing PC micrometastases after systemic administration. 211At-6 also showed uptake in renal proximal tubules resulting in late nephrotoxicity, highlighting the importance of long-term toxicity studies and microscale dosimetry.

KW - Alpha emitter

KW - Astatine

KW - Oncology: GU

KW - Prostate cancer

KW - Prostate-specific membrane antigen

KW - Radiation dosimetry

KW - Radionuclide therapy

KW - Radiopharmaceuticals

UR - http://www.scopus.com/inward/record.url?scp=84991376228&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84991376228&partnerID=8YFLogxK

U2 - 10.2967/jnumed.116.174300

DO - 10.2967/jnumed.116.174300

M3 - Article

VL - 57

SP - 1569

EP - 1575

JO - Journal of Nuclear Medicine

T2 - Journal of Nuclear Medicine

JF - Journal of Nuclear Medicine

SN - 0161-5505

IS - 10

ER -